Holen Sie sich die Stockscreener-App
1.81
0.55%
-0.01
Schlusskurs vom Vortag:
$1.82
Offen:
$1.85
24-Stunden-Volumen:
1.49M
Relative Volume:
0.86
Marktkapitalisierung:
$266.60M
Einnahmen:
$72,500
Nettoeinkommen (Verlust:
$-45.96M
KGV:
-2.6563
EPS:
-0.6814
Netto-Cashflow:
$-44.56M
1W Leistung:
+7.74%
1M Leistung:
-27.60%
6M Leistung:
+70.75%
1J Leistung:
+126.82%
1-Tages-Spanne:
$1.75
$1.89
1-Wochen-Bereich:
$1.54
$1.89
52-Wochen-Spanne:
$0.7406
$2.9489
Inflarx Nv Stock (IFRX) Company Profile
Compare IFRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IFRX
Inflarx Nv
|
1.81 | 266.60M | 72,500 | -45.96M | -44.56M | -0.6814 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Inflarx Nv Stock (IFRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-03 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-09-02 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-05-29 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-04-05 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-02-28 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-10-28 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2021-03-11 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-06 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-10-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2020-04-30 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-06-05 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2019-06-05 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-06-05 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2019-06-05 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-06-05 | Herabstufung | SunTrust | Buy → Hold |
| 2019-01-29 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-12-10 | Eingeleitet | Credit Suisse | Outperform |
| 2018-07-13 | Eingeleitet | BMO Capital Markets | Outperform |
| 2018-06-28 | Eingeleitet | Raymond James | Outperform |
| 2018-06-28 | Eingeleitet | SunTrust | Buy |
| 2018-02-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Inflarx Nv Aktie (IFRX) Neueste Nachrichten
InflaRx NV (IFRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
InflaRx NV (IFRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
InflaRx NV (IFRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
InflaRx NV (IFRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
InflaRx NV (IFRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
InflaRx StockAnalyst views and trading setup midweek - AD HOC NEWS
InflaRx NV (IFRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
InflaRx NV (IFRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
IFRX Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Cost Discipline, Though Stock DeclinesStrong Earnings Momentum - newsline.com
InflaRx NV (IFRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
InflaRx N.V. Q1 2026 Earnings: Narrower-than-Expected Loss Despite Stock DeclineEarnings Growth Forecast - newsline.com
IFRX Q1 2026 Earnings: Narrower-than-Expected Loss Amid Clinical Progress; Stock SlipsPost-Announcement Reaction - newsline.com
What Do Analysts Say About InflaRx N.V. (IFRX)? - Insider Monkey
InflaRx N.V. (IFRX) Q1 2026 Earnings: EPS Exceeds Expectations as Drug Development Advances - newsline.com
IFRX Q4 2025 Earnings: Narrower-than-Expected Loss Fails to Stem Stock DeclinePre-Earnings Drift - newsline.com
InflaRx prices $150 million share offering at $2 per share - Investing.com
InflaRx to develop izicopan for kidney disease treatment - Investing.com
InflaRx prices $150 million share offering at $2 per share By Investing.com - Investing.com Australia
INFLARX NV (IFRX) Stock Chart - ChartMill
InflaRx stock surges on AAV drug development plan - Investing.com
InflaRx investor update: Izicopan set to take center stage in AAV and renal disease pipeline - MSN
InflaRx NV stock (NL0012661870): Nasdaq-listed biotech trades lower ahead of next earnings update - AD HOC NEWS
Wall Street Firms Upgrade InflaRx Following Strategic Kidney Disease Focus - HarianBasis.co
Raymond James Upgrades InflaRx Following Clinical Shift - asatunews.co.id
InflaRx N.V. (IFRX) Edges Higher with Modest Gains, Tests Key Resistance ZoneHigh Volume Stocks - The Legal Advocate
Here’s Why InflaRx (IFRX) is Among the 10 Most Volatile Penny Stocks to Buy Now - Yahoo Finance
5 Most Volatile Penny Stocks to Buy Now - Insider Monkey
InflaRx N.V. Shows Resilience: IFRX Stock Edges Higher on Modest VolumePCR Spike - newsline.com
InflaRx N.V. (IFRX) Tumbles 7% as Shares Test Key Support LevelsSmart Beta Flow - newsline.com
InflaRx (IFRX) Surges Nearly 5%, Testing Key Resistance at $2.88Last Point Support - thelegaladvocate.com
IFRX - Finviz
InflaRx (IFRX) Q4 2025 Earnings: Slight EPS Beat Amid Pre‑Revenue PhaseStrong Earnings Momentum - The Legal Advocate
InflaRx N.V. (IFRX) Q4 2025 Earnings: Narrower Loss and Pipeline Progress Lift Sentiment - thelegaladvocate.com
InflaRx N.V. (IFRX) Surges 7.5% as Shares Test Key Resistance LevelWave Equality - The Legal Advocate
Long term debt to total assets ratio of InflaRx N.V. – HAM:IF0 - TradingView
Discontinued operations of InflaRx N.V. – HAM:IF0 - TradingView
EBIT per share of InflaRx N.V. – HAM:IF0 - TradingView
EBITDA per share of InflaRx N.V. – HAM:IF0 - TradingView
EBITDA of InflaRx N.V. – HAM:IF0 - TradingView
InflaRx N.V. Cash Flow – HAM:IF0 - TradingView
InflaRx N.V. Balance Sheet – HAM:IF0 - TradingView
InflaRx N.V. Statistics – HAM:IF0 - TradingView
Non-controlling/minority interest of InflaRx N.V. – HAM:IF0 - TradingView
InflaRx N.V. (IFRX) Stock Analysis: +2.11% Gain — What to Watch 2026-05-20Zigzag Correction - newsline.com
InflaRx NV stock (NL0012661870): what’s behind the latest trading volatility after Gohibic’s slo - AD HOC NEWS
InflaRx regains Nasdaq compliance after shares trade above $1 - MSN
InflaRx to develop izicopan for kidney disease treatment By Investing.com - Investing.com Nigeria
InflaRx N.V. (IFRX) Up +1.26% — Is There More Room to Run? 2026-05-18Upthrust Pattern - newsline.com
InflaRx NV stock (NL0012661870): May data from a recent YTD ranking - AD HOC NEWS
InflaRx NV (IFRX) price target decreased by 17.33% to 9.03 - MSN
Farallon funds and managers report shared stakes in InflaRx (IFRX) - Stock Titan
Finanzdaten der Inflarx Nv-Aktie (IFRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):